GlassScriptPhysician profile
Song Ching Ong
NPI 1104080803
$35,879.49
in general payments reported to CMS, 2019-2025
9 companies · $5,312 in 2025
The $5,312 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $2,629 · 2021: $3,623 · 2022: $6,011 · 2023: $12K · 2024: $5,841 · 2025: $5,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $10K · Consulting Fee: $9,244 · Travel and Lodging: $2,837 · Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,375.00 |
| Consulting Fee | $9,243.62 |
| Travel and Lodging | $2,837.22 |
| Food and Beverage | $1,011.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $24,022.15 | 2020-2023 | Procysbi |
| Amgen INC. | $6,048.05 | 2024-2025 | Procysbi |
| Calliditas Therapeutics US INC. | $4,706.02 | 2024-2025 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $409.38 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $325.00 | 2019-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $119.04 | 2023 | Livtencity |
| Novartis Pharmaceuticals Corporation | $111.08 | 2025 | |
| Mallinckrodt Hospital Products INC. | $100.55 | 2020 | |
| Vifor Pharma, INC. | $38.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Song Ching Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.